Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 712 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Terminated Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03738423
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
REGN3500, REGN3500-Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

NCT05186805
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Thousand Oaks, California • Centennial, Colorado • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 30, 2026, 6:23 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT05048056
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, AK120
Drug
Lead sponsor
Akesobio Australia Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Canoga Park, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 30, 2026, 6:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis

NCT03559075
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

NCT04718870
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

NCT01806662
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ustekinumab, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 30, 2026, 6:23 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

NCT01782703
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
0 Months to 17 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Northbrook, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 3 Interventional

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT02896101
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 4 Interventional

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

NCT07006792
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Not applicable Interventional Results available

Cooling Pillow for Atopic Dermatitis

NCT01132651
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Current standard eczema treatment and standard pillow at night, Chillow cooling pillow
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 30, 2026, 6:23 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

NCT06055361
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo
Drug
Lead sponsor
Brexogen Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 30, 2026, 6:23 PM EDT
Terminated Not applicable Interventional

A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema

NCT01826630
View directory record Official record
Conditions
Eczema, Hand Eczema, Atopic Dermatitis
Interventions
CLn BodyWash, Cetaphil Daily Facial Cleanser
Other
Lead sponsor
Shari L Hand
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gahanna, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 30, 2026, 6:23 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

NCT07660835
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
6 Months to 23 Months
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Not applicable Interventional

Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management

NCT01660217
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
A written Eczema Action Plan (EAP)
Other
Lead sponsor
Dermatology & Aesthetics of Wicker Park
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

NCT07172321
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

NCT06181435
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Scottsdale, Arizona • Tucson, Arizona • Lomita, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 6:23 PM EDT
Terminated Not applicable Interventional Results available

Vitamin D Deficiency and Atopic Dermatitis

NCT01337635
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency
Interventions
Vitamin D
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 30, 2026, 6:23 PM EDT
Completed No phase listed Observational

Bone Health in Patients With Atopic Dermatitis

NCT03800004
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 30, 2026, 6:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

NCT03770858
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Scratch sensor
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
2 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 30, 2026, 6:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

NCT05486208
View directory record Official record
Conditions
Healthy, Dermatitis, Atopic
Interventions
LY3844583, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:23 PM EDT
Recruiting Phase 2 Interventional

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GHZ339, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 6:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

NCT05590338
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Cypress, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 30, 2026, 6:23 PM EDT